Skip to main content


Log in

Characterization of Candida parapsilosis complex strains isolated from invasive fungal infections

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript


In the present work, we studied the distribution of Candida parapsilosis complex species and the antifungal susceptibility of clinical isolates collected during an Italian surveillance study of yeast invasive fungal infections (IFIs) in intensive care units (ICUs). Minimum inhibitory concentrations (MICs) were determined using the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method. BanI digestion patterns of the secondary alcohol dehydrogenase polymerase chain reaction (PCR) products were used to identify C. parapsilosis sensu stricto, C. orthopsilosis, and C. metapsilosis. A total of 138 C. parapsilosis isolates were stored (January 2007–December 2008). The overall frequency of C. parapsilosis complex in IFIs was 22%. Of the 138 tested isolates, 95% were C. parapsilosis sensu stricto, 3.6% were C. orthopsilosis, and 1.4% were C. metapsilosis. The MIC50 values (expressed as μg/ml) for anidulafungin, caspofungin, and micafungin for C. parapsilosis complex were 2, 1, and 2, respectively, and the MIC90 values were 4, 2, and 4, respectively. The MIC50 and MIC90 values for itraconazole and posaconazole were 0.12 and 0.25, respectively, and for fluconazole, they were 1 and 4, respectively. This study, the most comprehensive study conducted to date to evaluate the frequency and antifungal susceptibility profiles of C. parapsilosis complex isolates from critically ill patients in Italy, highlights the low prevalence of C. orthopsilosis and C. metapsilosis in IFIs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others


  1. St-Germain G, Laverdière M, Pelletier R et al (2008) Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005. Can J Infect Dis Med Microbiol 19:55–62

    PubMed  Google Scholar 

  2. van Hal SJ, Marriott DJ, Chen SC et al; Australian Candidaemia Study (2009) Candidemia following solid organ transplantation in the era of antifungal prophylaxis: the Australian experience. Transpl Infect Dis 11:122–127

    Article  PubMed  Google Scholar 

  3. Eggimann P, Garbino J, Pittet D (2003) Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 3:685–702

    Article  PubMed  Google Scholar 

  4. Shorr AF, Lazarus DR, Sherner JH et al (2007) Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit Care Med 35:1077–1083

    Article  PubMed  Google Scholar 

  5. Tortorano AM, Biraghi E, Astolfi A et al; FIMUA Candidemia Study Group (2002) European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. J Hosp Infect 51:297–304

    Article  PubMed  CAS  Google Scholar 

  6. Almirante B, Rodríguez D, Cuenca-Estrella M et al (2006) Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case–control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 44:1681–1685

    Article  PubMed  Google Scholar 

  7. Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20:133–163

    Article  PubMed  CAS  Google Scholar 

  8. Shin JH, Kee SJ, Shin MG et al (2002) Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol 40:1244–1248

    Article  PubMed  Google Scholar 

  9. Tavanti A, Davidson AD, Gow NA et al (2005) Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 43:284–292

    Article  PubMed  CAS  Google Scholar 

  10. Gonçalves SS, Amorim CS, Nucci M et al (2010) Prevalence rates and antifungal susceptibility profiles of the Candida parapsilosis species complex: results from a nationwide surveillance of candidaemia in Brazil. Clin Microbiol Infect 16:885–887. doi: 10.1111/j.1469-0691.2009.03020.x

    PubMed  Google Scholar 

  11. Gomez-Lopez A, Alastruey-Izquierdo A, Rodríguez D et al; Barcelona Candidemia Project Study Group (2008) Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrob Agents Chemother 52:1506–1509

    Article  PubMed  CAS  Google Scholar 

  12. Lockhart SR, Messer SA, Pfaller MA et al (2008) Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J Clin Microbiol 46:2659–2664

    Article  PubMed  CAS  Google Scholar 

  13. Szabó Z, Szilágyi J, Tavanti A et al (2009) In vitro efficacy of 5 antifungal agents against Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis as determined by time–kill methodology. Diagn Microbiol Infect Dis 64:283–288

    Article  PubMed  Google Scholar 

  14. Clinical and Laboratory Standards Institute (CLSI) (2008) Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd edn. Approved standard M27-205 A3. CLSI, Wayne, PA

  15. Clinical and Laboratory Standards Institute (CLSI) (2008) Reference method for broth dilution antifungal susceptibility testing of yeasts—Third Informational Supplement, M27-S3. CLSI, Wayne, PA

  16. Pfaller MA, Castanheira M, Messer SA et al (2011) Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn Microbiol Infect Dis 69:45–50

    Article  PubMed  CAS  Google Scholar 

  17. Pfaller MA, Diekema DJ, Jones RN et al (2002) Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 40:852–856

    Article  PubMed  CAS  Google Scholar 

  18. Pfaller MA, Boyken L, Hollis RJ et al (2010) Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol 48:52–56

    Article  PubMed  CAS  Google Scholar 

  19. Silva AP, Miranda IM, Lisboa C et al (2009) Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital. J Clin Microbiol 47:2392–2397

    Article  PubMed  CAS  Google Scholar 

  20. Jacobson MJ, Piper KE, Nguyen G et al (2008) In vitro activity of anidulafungin against Candida albicans biofilms. Antimicrob Agents Chemother 52:2242–2243

    Article  PubMed  CAS  Google Scholar 

  21. Pemán J, Cantón E, Valentín A (2008) Activity of anidulafungin against Candida biofilms [in Spanish]. Rev Iberoam Micol 25:124–128

    Article  PubMed  Google Scholar 

  22. Katragkou A, Chatzimoschou A, Simitsopoulou M et al (2008) Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob Agents Chemother 52:357–360

    Article  PubMed  CAS  Google Scholar 

  23. Garcia-Effron G, Katiyar SK, Park S et al (2008) A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 52:2305–2312

    Article  PubMed  CAS  Google Scholar 

Download references


This work was sponsored by Pfizer Italia, Srl.

We would like to thank Arianna Tavanti (Department of Biology, University of Pisa, Italy) for supplying the ATCC strains.

Collection of the C. parapsilosis strains was part of an Italian surveillance study (GISIA3). Members of the GISIA3 group (Gruppo Italiano per lo Studio In vitro degli Antifungini) included: G. Amato, M.M. Piccirillo, L. Degl’Innocenti (Cardarelli Hospital, Naples, Italy); S. Andreoni, M.R. Fanello (Maggiore della Carità Hospital, Novara, Italy); C. Farina, S. Perin (San Carlo Hospital, Milan, Italy); R. Fontana, G. Lo Cascio, L. Maccarano (GB Rossi Hospital, Verona, Italy); G. Gesu, G. Lombardi, G. Ortisi (Niguarda Ca’ Granda Hospital, Milan, Italy); F. Luzzaro, G. Brigante (Circolo Hospital, Varese, Italy); E. Manso, Am. Calvo, C. Cutrini (Torrette Hospital, Ancona, Italy); M. Mussap, O. Soro (San Martino Hospital, Genoa, Italy); A. Nanetti, E. Tangorra (University of Bologna, Bologna, Italy); P. Nicoletti, P. Pecile, C. Bertellini (Careggi Hospital, Florence, Italy); R. Rigoli, L. Campion (Ca’ Foncello Hospital, Treviso, Italy); M. Tronci, G. Parisi, (Forlanini Hospital, Rome, Italy); M.T. Montagna, R. Iatta, T. Cuna (Università degli Studi di Bari, Italy); G. Morace, E. Borghi, C. Biassoni, M. La Francesca, R. Sciota (Università degli Studi di Milan, Italy); S. La Face, I. Mancuso (Pfizer Italia, Srl, Rome, Italy).

Author information

Authors and Affiliations


Corresponding author

Correspondence to E. Borghi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Borghi, E., Sciota, R., Iatta, R. et al. Characterization of Candida parapsilosis complex strains isolated from invasive fungal infections. Eur J Clin Microbiol Infect Dis 30, 1437–1441 (2011).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: